The 36-month beta value for AUPH is at 1.36. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AUPH is 127.86M, and currently, shorts hold a 8.33% of that float. The average trading volume for AUPH on April 02, 2024 was 2.40M shares.
AUPH) stock’s latest price update
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)’s stock price has plunge by 7.78relation to previous closing price of 5.01. Nevertheless, the company has seen a 8.65% surge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-02-15 that Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago.
AUPH’s Market Performance
Aurinia Pharmaceuticals Inc (AUPH) has seen a 8.65% rise in stock performance for the week, with a -5.59% decline in the past month and a -41.68% plunge in the past quarter. The volatility ratio for the week is 3.74%, and the volatility levels for the past 30 days are at 3.76% for AUPH. The simple moving average for the past 20 days is 2.92% for AUPH’s stock, with a -35.42% simple moving average for the past 200 days.
Analysts’ Opinion of AUPH
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AUPH reach a price target of $25, previously predicting the price at $34. The rating they have provided for AUPH stocks is “Overweight” according to the report published on May 05th, 2022.
Oppenheimer gave a rating of “Outperform” to AUPH, setting the target price at $31 in the report published on December 10th of the previous year.
AUPH Trading at -16.11% from the 50-Day Moving Average
After a stumble in the market that brought AUPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.56% of loss for the given period.
Volatility was left at 3.76%, however, over the last 30 days, the volatility rate increased by 3.74%, as shares sank -6.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.47% lower at present.
During the last 5 trading sessions, AUPH rose by +8.65%, which changed the moving average for the period of 200-days by -45.73% in comparison to the 20-day moving average, which settled at $5.23. In addition, Aurinia Pharmaceuticals Inc saw -39.93% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUPH starting from Greenleaf Peter, who sale 126,981 shares at the price of $5.60 back on Mar 06 ’24. After this action, Greenleaf Peter now owns 1,522,114 shares of Aurinia Pharmaceuticals Inc, valued at $711,094 using the latest closing price.
Robertson Stephen P., the EVP, General Counsel of Aurinia Pharmaceuticals Inc, sale 57,745 shares at $5.60 during a trade that took place back on Mar 06 ’24, which means that Robertson Stephen P. is holding 443,824 shares at $323,372 based on the most recent closing price.
Stock Fundamentals for AUPH
Current profitability levels for the company are sitting at:
- -0.47 for the present operating margin
- 0.92 for the gross margin
The net margin for Aurinia Pharmaceuticals Inc stands at -0.44. The total capital return value is set at -0.18. Equity return is now at value -19.92, with -15.31 for asset returns.
Based on Aurinia Pharmaceuticals Inc (AUPH), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -0.34. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is 79.52.
Currently, EBITDA for the company is -71.67 million with net debt to EBITDA at -0.77. When we switch over and look at the enterprise to sales, we see a ratio of 4.73. The receivables turnover for the company is 7.29for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.50.
Conclusion
In conclusion, Aurinia Pharmaceuticals Inc (AUPH) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
